MarketLens

Log in
Stock AnalysisPro

What Did Ascentage Pharma Present at ASCO 2026

1 months ago
SHARE THIS ON:

What Did Ascentage Pharma Present at ASCO 2026

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

What Did D3 Bio Present at ASCO 2026 for Elisrasib

What Did D3 Bio Present at ASCO 2026 for Elisrasib

1 months ago
What Makes Elisrasib's ASCO 2026 Data So Significant

What Makes Elisrasib's ASCO 2026 Data So Significant

1 months ago
What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

4 months ago
What Makes Akeso's ASCO 2026 Plenary Session So Crucial

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

1 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCryptoNew Release

You may also like

Stock News•1 months ago

2026 ASCO LBA | Juncell Therapeutics' GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma

Juncell Therapeutics' GC101 TIL therapy met its primary endpoint in a pivotal Phase II trial for advanced melanoma patients who failed PD-1 antibody treatment. The clinical success, presented at the 2...
Stock News•1 months ago

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Ellipses Pharma and partner Kelun-Biotech will present pivotal trial data for EP0031 (lunbotinib) at the ASCO 2026 meeting, held May 29 to June 2. The data evaluates the efficacy and safety of the nex...
SRI
Stock News•2 months ago

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Ascentage Pharma released six clinical study abstracts for the 2026 ASCO Annual Meeting, featuring three lead drug candidates. Three of these studies were selected for rapid oral presentations, highli...
AAPG
Stock News•2 months ago

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Crescent Biopharma will present a trial-in-progress poster for its ASCEND Phase 1/2 study of CR-001 at the ASCO 2026 Annual Meeting. The study evaluates the PD-1 x VEGF bispecific antibody across mult...
CBIO

Breaking News

View All →
Earnings
Regional Banks
Earnings Surprise
Biotech & Pharma
Corporate Earnings
Debt/Share Issuance
Financials
Free Cash Flow (FCF)
M&A
Radiopharmaceuticals

Featured Articles

Fastly's Insider Exodus: Why CEO Sales Signal Caution Despite AI Hype

Fastly's Insider Exodus: Why CEO Sales Signal Caution Despite AI Hype

12 minutes ago
Safety Insurance's Persistent Insider Exodus Signals Deeper Cracks Beneath Its Dividend Lure

Safety Insurance's Persistent Insider Exodus Signals Deeper Cracks Beneath Its Dividend Lure

13 minutes ago
Major Shareholder's $1 Million CACC Stock Sale Signals Caution Ahead of Earnings

Major Shareholder's $1 Million CACC Stock Sale Signals Caution Ahead of Earnings

14 minutes ago

Top Headlines

View More →
Stock News•38 minutes ago

Rosen Law Firm Encourages Alibaba Group Holding Limited Investors to Inquire About Securities Class Action Investigation - BABA

Stock News•1 hour ago

Jimothy keeps on giving: Amazon and others match winning bid for raccoon art, to benefit food bank

Stock News•1 hour ago

Chipotle Mexican Grill (CMG) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Microsoft (MSFT) Ascends While Market Falls: Some Facts to Note

Stock News•1 hour ago

Securities Fraud Investigation Into Alphabet Inc. (GOOG) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz